Nuvation Bio Inc.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. Its lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor designed to treat patients with ROS1-positive non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1, currently in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma. Founded in 2018 and headquartered in New York, New York, Nuvation Bio operates in the biotechnology industry within the healthcare sector, aiming to address unmet medical needs in oncology.

Nuvation Bio Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol NUVB. The company trades in US dollars (USD), as it is based in the United States. Being listed on a major US exchange provides liquidity and visibility to investors, and the use of USD facilitates trading for both domestic and international investors.

Nuvation Bio Inc. operates in the healthcare sector, specifically within the biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing drug candidates for cancer treatment. Biotechnology companies like Nuvation Bio typically engage in high-risk, high-reward research, aiming to bring innovative therapies to market. The company's primary area of focus is oncology, with its lead programs targeting specific genetic mutations in cancers such as non-small cell lung cancer and astrocytoma.

Nuvation Bio Inc. is headquartered in New York, New York, United States. As a clinical-stage company, its primary market is the United States, where it conducts clinical trials and seeks regulatory approvals. The company's therapies are designed to address global cancer treatment needs, but its current operations and clinical development are centered in the US. The company was founded in 2018 and has since been advancing its pipeline of oncology candidates.

Nuvation Bio Inc.'s main product candidates include IBTROZI (taletrectinib) and Safusidenib. IBTROZI is a ROS1 inhibitor being developed for the treatment of patients with ROS1-positive non-small cell lung cancer, a type of lung cancer driven by ROS1 gene fusions. Safusidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), currently in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma, a type of brain tumor. Both candidates target specific genetic alterations in cancers, reflecting the company's precision medicine approach.